Sopan Pharmaceuticals Limited IPO Opens From Today, Priority Given to Nepalis Working Abroad

Sopan Pharmaceuticals Limited has opened its Initial Public Offering (IPO) from today (March 22/Chaitra 9) targeting Nepalis working abroad. Sopan Pharmaceuticals Limited has received approval to issue 42.9 million shares worth Rs. 429 million, which is 25 percent of its issued capital of Rs. 1.716 billion. Out of the total shares, 10 percent (429,000 units) have been allocated specifically for Nepalis working abroad, while 5 percent has been reserved for mutual funds and 4 percent for company employees. The remaining 3,474,900 shares will be issued to the general public. Investors can apply for a minimum of 10 shares and a maximum of 11,000 shares, and foreign-employed Nepalis can submit applications until Chaitra 12. The issue manager of the IPO is NMB Capital Limited, and applications can be submitted through the Mero Share platform and the C-ASBA system. For the IPO, CARE Ratings Nepal has assigned the company a CARE-NP B issuer rating, indicating a high level of risk in its capacity to meet financial obligations. The company has stated that the simple payback period is 8.11 years, while the discounted payback period is 11.35 years.